Please assess the completion status of the following clinical trial:

Trial Title: Techniques to Improve Efficacy of Second Trimester Medical Termination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 14-24 weeks pregnant~* planned medical termination~* able to speak and understand English~* no contraindication to prostaglandins~Exclusion Criteria:~* gestation \< 13 weeks~* allergy/contraindication to misoprostol~* allergy/contraindication to mifepristone~* fetal demise

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Vaginal misoprostol (Type: ACTIVE_COMPARATOR): Women allocated to the vaginal misoprostol management protocol will receive a loading dose of 800 mcg misoprostol vaginally followed in 4 hours by 400 mcg vaginal misoprostol, the latter repeated every 4 hours for a maximum of 4 doses.~If abortion does not occur within 24 hours of commencement of this regimen, the sequence will be repeated.~If delivery is not accomplished within 48 hours of prostaglandin commencement, a transcervical Foley catheter will be inserted and a solution of prostaglandin F2 alpha infused 2-hourly until delivery occurs.
- Oral misoprostol (Type: ACTIVE_COMPARATOR): Women allocated to the standard management protocol will receive a loading dose of 800 mcg misoprostol vaginally followed in 3 hours by 400 mcg misoprostol orally, the latter repeated every 3-hours to a maximum of 4 oral doses.~If abortion does not occur within 24 hours of commencement of this regimen, the sequence will be repeated.~If delivery is not accomplished within 48 hours of prostaglandin commencement, a transcervical Foley catheter will be inserted and a solution of prostaglandin F2 alpha infused 2-hourly until delivery occurs.
- Sublingual misoprostol (Type: ACTIVE_COMPARATOR): Women allocated to the sublingual misoprostol protocol will receive a loading dose of 800 mcg misoprostol vaginally followed in 3 hours by 400 mcg sublingual misoprostol, the latter repeated every 3 hours for a maximum of 4 doses.~If abortion does not occur within 24 hours of commencement of this regimen, the sequence will be repeated.~If delivery is not accomplished within 48 hours of prostaglandin commencement, a transcervical Foley catheter will be inserted and a solution of prostaglandin F2 alpha infused 2-hourly until delivery occurs.

Based on this trial design, predict the completion outcome and termination type (if applicable).